Published

07 Dec 25

Updated

06 Aug 26

Views

323

Not Invested

Fair Value

US$14.5

Share price06 Aug

US$7.7846.3% undervalued

Loading

1Y107.47%

7D13.58%

Gene And Immunotherapy Expansion Will Drive Durable Long Term Opportunity

AN

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

07 Dec 25

Updated

06 Aug 26

Views

323

Not Invested

Shared on 06 Aug 26

Fair value Increased 16%

PGEN: Orphan Exclusivity And Early RRP Uptake Will Drive Future Upside

Precigen gets a boost as its PAPZIMEOS launch comes in stronger than expected and the FDA grants it a period of protection from copycat competition. The key question now is whether early patient demand and insurance coverage hold up long enough to reduce the company’s reliance on this one product.

10 views

Shared on 26 Jun 26

Fair value Increased 46%

PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside

Precigen’s PAPZIMEOS gets a stronger backdrop as regulators grant a period where similar rival treatments can’t easily enter, and longer-term follow-up suggests many patients keep benefiting for years without new safety surprises. Analysts respond by lifting their view of what the business could be worth, while still flagging that future results need to keep matching the early launch momentum.

63 views

Fair Value vs Share Price

US$14.5

vs US$7.7846.3% undervalued

91.4%

Revenue growth

60.5%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Precigen

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Exceptional growth potential with low risk.

Market capUS$2.8b

PB63.9x

Estimated Growth34.8%

Dividend YieldN/A

CEO & management

Helen Sabzevari

CEO

6.7yrs

CEO Tenure

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.